NCT06559722

A Trial Investigating the Efficacy and Safety of Insulin Degludec/Liraglutide Injection in Subjects With Type 2 Diabetes

A 26-Week,Randomised,Open-Label,Multicenter,Active-Controlled,Parallel-Design,Phase III Clinical Trial to Compare the Efficacy and Safety of Insulin Degludec/Liraglutide Injection With XULTOPHY® Once Daily Via Subcutaneous Injection in Chinese Subjects With Type 2 Diabetes

• Status: Not Yet Recruiting
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 510 (estimated)
• Sponsor: Tonghua Dongbao Pharmaceutical Co.,Ltd · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

This is a randomised, open-label, multicenter, active-controlled, parallel-design, phase III clinical trial. The purpose of this study to compare the efficacy and safety of Insulin Degludec/Liraglutide Injection with XULTOPHY® once daily via subcutaneous injection in Chinese Subjects with Type 2 Diabetes.

Conditions

• Type 2 Diabetes

Interventions

Type	Name	Description
DRUG	Insulin Degludec/liraglutide Injection	Subcutaneously (s.c., under the skin)administration once daily in combination with metformin. Dose was individually adjusted.
DRUG	XULTOPHY®	Subcutaneously (s.c., under the skin)administration once daily in combination with metformin. Dose was individually adjusted.

Timeline

• Start date: 2024-08-01
• Primary completion: 2025-10-01
• Completion: 2026-02-01
• First posted: 2024-08-19
• Last updated: 2024-08-19